Patient-Reported Outcomes Show Benefits of Isatuximab On-Body Injector in Myeloma: With Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO
Season 14, Episode 41, Nov 05, 11:50 PM
Share
Subscribe
Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.
In today’s episode, we had the pleasure of speaking with Sikander Ailawadhi, MD, and Beth Faiman, PhD, MS, APN-BC, BMTCN, AOCN, FAAN, FAPO, about the potential clinical implications of the phase 3 IRAKLIA (NCT05405166) and phase 2 IZALCO (NCT05704049) studies, which investigated the use of isatuximab-irfc (Sarclisa) administered via an on-body delivery system in patients with relapsed/refractory multiple myeloma. Ailawadhi is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Jacksonville, Florida. Faiman is a nurse practitioner in the Multiple Myeloma Program at Cleveland Clinic in Ohio.
In our exclusive interview, Ailawadhi and Faiman discussed the rationale for efforts to bring isatuximab on-body injectors into the clinic, key patient-reported outcome findings from these studies, and how these findings may one day influence therapy administration across the broader multiple myeloma treatment paradigm.
In our exclusive interview, Ailawadhi and Faiman discussed the rationale for efforts to bring isatuximab on-body injectors into the clinic, key patient-reported outcome findings from these studies, and how these findings may one day influence therapy administration across the broader multiple myeloma treatment paradigm.